Clinical trial results show a 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts.
from Latest Science News -- ScienceDaily https://ift.tt/2FPDOXL
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment